SG
AKTX

StoneX Group’s Akari Therapeutics AKTX Stock Holding History

StoneX Group’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-532
Closed -$6.15K – 924
2025
Q4 		$6.15K Buy
+532
New +$12.4K ﹤0.01% 1022

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

StoneX Group's AKTX Position: Q1 2026 in Review

StoneX Group sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 532 shares — an estimated $6.15K sold.

StoneX Group first reported a position in AKTX in Q4 2025 and held it in 1 quarter. The position peaked at $6.15K in Q4 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • StoneX Group reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • StoneX Group sold 532 Akari Therapeutics shares in Q1 2026, an estimated $6.15K.
  • StoneX Group first reported a position in Akari Therapeutics in Q4 2025 and held it in 1 quarter.
  • StoneX Group's Akari Therapeutics position peaked at $6.15K in Q4 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.